Daurismo
Active Ingredient(s): GlasdegibFDA Approved: * November 21, 2018
Pharm Company: * PFIZER INC
Category: Cancer
Glasdegib, sold under the brand name Daurismo, is a medication for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults older than 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy.[3][4][5] It is taken by mouth and is used in combination with low-dose cytarabine.[4] The recommended dose of glasdegib is 100 mg orally once daily on days 1 to 28 in combination with cyt... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.